Companies 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics (FDMT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me 4D Molecular Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $10,286,808FY2023
- $1,009,004FY2024
- $2,051,343FY2025
CEO total pay was $2,051,343 in fiscal 2025, up from $1,009,004 in fiscal 2024.
FY2025: salary $667,252 · bonus $0 · stock awards $0 · option awards $822,750
Executives and directors
David Kirn · CEOKristian Humer · CFOFariborz Kamal · PresidentCharles Theuer, M.D., Ph.D · Independent DirectorGlenn Sblendorio · Independent DirectorJacob Chacko, M.D., MBA · Independent DirectorJohn F. Milligan, Ph.D · Chair of the BoardNancy Miller-Rich · Independent DirectorShawn Cline Tomasello, MBA · Independent DirectorSusannah Gray, MBA · Independent Director
Frequently asked questions
Who was the highest-paid executive at 4D Molecular Therapeutics, Inc. in fiscal 2025?
As disclosed, Kristian Humer (Chief Financial Officer) was the highest-paid executive at 4D Molecular Therapeutics, Inc. in fiscal 2025, with total compensation of $3,990,903.
How did shareholders vote on 4D Molecular Therapeutics, Inc.'s executive compensation?
As disclosed, 97.46% of shareholders supported 4D Molecular Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does 4D Molecular Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, 4D Molecular Therapeutics, Inc. reported total board compensation of $460,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kristian Humer | $66,000 | $50,000 | $0 | $3,874,656 | $0 | $0 | $247 | $3,990,903 |
| Chief Financial Officer | ||||||||
| David Kirn | 667,252 | 0 | 0 | 822,750 | 560,597 | 0 | 744 | 2,051,343 |
| President and Chief Executive Officer | ||||||||
| Fariborz Kamal | 551,743 | 0 | 0 | 548,705 | 339,513 | 0 | 1,612 | 1,441,573 |
| Former Chief Operating Officer & President | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kristian Humer | $3,990,903 | — | — | — |
| David Kirn | 2,051,343 | 1,009,004 | 10,286,808 | ↑ +1,042,339 |
| Fariborz Kamal | 1,441,573 | 734,607 | 4,544,260 | ↑ +706,966 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We seek to ensure that the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford (part of the Rewards Solutions practice at Aon plc) |
| Clawback policy | True |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Kirn | Option | — | — | — | — | — | $822,750 |
| Kristian Humer | Option | — | — | — | — | — | 3,874,656 |
| Fariborz Kamal | Option | — | — | — | — | — | 548,705 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Kirn | $0 | $0 | $822,750 | 0.0% |
| Kristian Humer | 0 | 0 | 3,874,656 | 0.0% |
| Fariborz Kamal | 0 | 0 | 548,705 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Fariborz Kamal | Option | 2,813 | 8.06 | — |
| Fariborz Kamal | Option | 2,917 | 15.78 | — |
| David Kirn | Option | 6,250 | 15.78 | — |
| Fariborz Kamal | Option | 11,250 | 8.04 | — |
| Fariborz Kamal | Option | 21,875 | 20.24 | — |
| David Kirn | Option | 64,750 | 20.24 | — |
| Fariborz Kamal | Option | 130,000 | 14.42 | — |
| Fariborz Kamal | Option | 144,950 | 4.14 | — |
| David Kirn | Option | 217,344 | 4.14 | — |
| David Kirn | Option | 295,000 | 14.42 | — |
| Kristian Humer | Option | 480,000 | 10.51 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John F. Milligan, Ph.DNot independent · Board Chair | $150,000 | $0 | $105,000 | — | $0 | $255,000 |
| Jacob Chacko, M.D., MBAIndependent · Audit (Chair) · Nominating/Governance | 65,000 | 0 | 70,000 | — | 0 | 135,000 |
| Susannah Gray, MBAIndependent · Audit · Compensation (Chair) | 65,000 | 0 | 70,000 | — | 0 | 135,000 |
| Charles Theuer, M.D., Ph.DIndependent · Audit · Nominating/Governance · Science and Technology (Chair) | 65,000 | 0 | 70,000 | — | 0 | 135,000 |
| Shawn Cline Tomasello, MBAIndependent · Compensation · Nominating/Governance (Chair) · Science and Technology | 62,500 | 0 | 70,000 | — | 0 | 132,500 |
| Nancy Miller-RichIndependent · Compensation · Science and Technology | 52,500 | 0 | 70,000 | — | 0 | 122,500 |
| David Kirn, M.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Glenn SblendorioIndependent · Compensation · Science and Technology · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $70,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $460,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $460,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names 4D Molecular Therapeutics as a peer
Companies that benchmark against FDMT
7 companies name FDMT as a compensation peer
- Adverum Biotechnologies, Inc.ADVMFY2024
- Cartesian Therapeutics, Inc.RNACFY2025
- Dianthus Therapeutics, Inc. /DE/DNTHFY2025
- Kodiak Sciences Inc.KODFY2025
- Opus Genetics, Inc.IRDFY2025
- PLIANT THERAPEUTICS, INC.PLRXFY2025
- Stoke Therapeutics, Inc.STOKFY2025
Each company listed discloses FDMT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named FDMT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | 4D Molecular Therapeutics, Inc. | 2025 | David Kirn | $667,252 | $0 | $822,750 | $560,597 | $2,051,343 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 36,065,437 | 940,414 | 67,379 | 97.46% | Passed |
| 2025 | 2025-06-17 | 31,841,967 | 394,002 | 35,446 | 98.78% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-17 | 97.46%a |
| 2025 | 2025-06-17 | 98.78%b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will also have no effect on Proposal 3.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will also have no effect on Proposal 3 and Proposal 4.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Kirn | Director | 2026-06-01 | D | 1,922 | $10 | $19,258 | Common, open-market sale | Form 4 ↗ |
| John F. Milligan | Director | 2026-06-17 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Theuer | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy Miller-Rich | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shawn Tomasello | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Chacko | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Glenn Sblendorio | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Kirn | Director | 2026-06-22 | D | 114,746 | 10 | 1,200,851 | Common, open-market sale | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-23 | D | 9,810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-23 | D | 9,810 | 12 | 117,720 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-23 | A | 9,810 | 4 | 40,613 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-30 | D | 5,752 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-30 | — | 814 | — | — | 1 insider, 1 accrual row | ||
| Scott Bizily | Chief Legal Officer | 2026-06-30 | A | 5,752 | 6 | 37,330 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-30 | A | 814 | 4 | 3,370 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-30 | D | 6,566 | 14 | 91,924 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-07-09 | D | 42,608 | 13 | 548,177 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-07-10 | D | 442 | 13 | 5,673 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-07-10 | D | 15,283 | 12 | 183,560 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-08-03 | D | 12,415 | 10 | 124,722 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-08-04 | D | 26,842 | 10 | 274,596 | Common, open-market sale | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-13 | — | 1,635 | — | — | 1 insider, 1 accrual row | ||
| Scott Bizily | Chief Legal Officer | 2026-08-13 | D | 1,635 | 12 | 19,620 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-08-13 | A | 1,635 | 4 | 6,769 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-17 | — | 1,635 | — | — | 1 insider, 1 accrual row | ||
| Scott Bizily | Chief Legal Officer | 2026-08-17 | D | 1,635 | 12 | 19,947 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-08-17 | A | 1,635 | 4 | 6,769 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-08-19 | D | 25,927 | 16 | 425,651 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-08-19 | D | 43,149 | 15 | 662,622 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-08-19 | A | 50,000 | 4 | 207,000 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-08-19 | D | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-01 | — | 584 | — | — | 1 insider, 1 accrual row | ||
| Scott Bizily | Chief Legal Officer | 2026-09-01 | D | 584 | 14 | 8,176 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-09-01 | A | 584 | 6 | 3,790 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-09-14 | D | 58,333 | 14 | 811,004 | Common, open-market sale | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-16 | — | 1,635 | — | — | 1 insider, 1 accrual row | ||
| Scott Bizily | Chief Legal Officer | 2026-09-16 | D | 1,635 | 14 | 22,318 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-09-16 | A | 1,635 | 4 | 6,769 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-10-05 | D | 272 | 14 | 3,702 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-10-05 | D | 58,061 | 13 | 750,235 | Common, open-market sale | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-16 | — | 1,635 | — | — | 1 insider, 1 accrual row | ||
| Scott Bizily | Chief Legal Officer | 2026-10-16 | D | 1,635 | 13 | 20,993 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-10-16 | A | 1,635 | 4 | 6,769 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 44 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Kirn | Director | 2026-06-01 | D | 1,922 | $10 | $19,258 | Common, open-market sale | Form 4 ↗ |
| John F. Milligan | Director | 2026-06-17 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susannah Gray | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Theuer | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy Miller-Rich | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shawn Tomasello | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Chacko | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Glenn Sblendorio | Director | 2026-06-17 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Kirn | Director | 2026-06-22 | D | 114,746 | 10 | 1,200,851 | Common, open-market sale | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-23 | D | 9,810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-23 | D | 9,810 | 12 | 117,720 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-23 | A | 9,810 | 4 | 40,613 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-30 | D | 5,752 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-30 | D | 814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-30 | A | 5,752 | 6 | 37,330 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-30 | A | 814 | 4 | 3,370 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-06-30 | D | 6,566 | 14 | 91,924 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-07-09 | D | 42,608 | 13 | 548,177 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-07-10 | D | 442 | 13 | 5,673 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-07-10 | D | 15,283 | 12 | 183,560 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-08-03 | D | 12,415 | 10 | 124,722 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-08-04 | D | 26,842 | 10 | 274,596 | Common, open-market sale | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-08-13 | D | 1,635 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-08-13 | D | 1,635 | 12 | 19,620 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-08-13 | A | 1,635 | 4 | 6,769 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-08-17 | D | 1,635 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-08-17 | D | 1,635 | 12 | 19,947 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-08-17 | A | 1,635 | 4 | 6,769 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-08-19 | D | 25,927 | 16 | 425,651 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-08-19 | D | 43,149 | 15 | 662,622 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-08-19 | A | 50,000 | 4 | 207,000 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-08-19 | D | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-09-01 | D | 584 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-09-01 | D | 584 | 14 | 8,176 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-09-01 | A | 584 | 6 | 3,790 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-09-14 | D | 58,333 | 14 | 811,004 | Common, open-market sale | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-09-16 | D | 1,635 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-09-16 | D | 1,635 | 14 | 22,318 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-09-16 | A | 1,635 | 4 | 6,769 | Common | Form 4 ↗ |
| David Kirn | Director | 2026-10-05 | D | 272 | 14 | 3,702 | Common, open-market sale | Form 4 ↗ |
| David Kirn | Director | 2026-10-05 | D | 58,061 | 13 | 750,235 | Common, open-market sale | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-10-16 | D | 1,635 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-10-16 | D | 1,635 | 13 | 20,993 | Common | Form 4 ↗ |
| Scott Bizily | Chief Legal Officer | 2026-10-16 | A | 1,635 | 4 | 6,769 | Common | Form 4 ↗ |
Sources (65 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kristian Humer. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table”. As printed: 3,990,903. View filing ↗
- Section 01, David Kirn. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table” · page 24. As printed: 2,051,343. View filing ↗
- Section 01, Fariborz Kamal. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table”. As printed: 1,441,573. View filing ↗
- Section 03, David Kirn Option. DEF 14A, filed 2026-04-28. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Kristian Humer Option. DEF 14A, filed 2026-04-28. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Fariborz Kamal Option. DEF 14A, filed 2026-04-28. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-18. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, John F. Milligan, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 255,000. View filing ↗
- Section 08, Jacob Chacko, M.D., MBA. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 135,000. View filing ↗
- Section 08, Susannah Gray, MBA. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 135,000. View filing ↗
- Section 08, Charles Theuer, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 135,000. View filing ↗
- Section 08, Shawn Cline Tomasello, MBA. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 132,500. View filing ↗
- Section 08, Nancy Miller-Rich. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 122,500. View filing ↗
- Section 08, David Kirn, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Glenn Sblendorio. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, David Kirn 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John F. Milligan 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susannah Gray 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Theuer 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Miller-Rich 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shawn Tomasello 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Chacko 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn Sblendorio 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-06-22. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-07-09. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-08-17. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-08-17. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-08-17. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-09-16. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-09-16. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-09-16. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-10-05. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Kirn 2026-10-05. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Bizily 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-22. Item 5.07 · say-on-pay result. As reported: 97.46% (votes for as printed: 36,065,437). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 98.78% (votes for as printed: 31,841,967). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 460,000 + equity 0 + all other 0 = 460,000, summed across the director compensation table rows.
- 4D Molecular Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in 4D Molecular Therapeutics, Inc.'s own proxy. As printed: 2,051,343. View filing ↗